Pharmacology of AMD3465: A small molecule antagonist of the chemokine receptor CXCR4

Biochemical Pharmacology

Volumn 78, Issue 8, 2009, Pages 993-1000

  Bodart, Veronique ^a   Anastassov, Virginia ^a   Darkes, Marilyn C ^a   Idzan, Stefan R ^a   Labrecque, Jean ^a   Lau, Gloria ^a   Mosi, Renee M ^a   Neff, Kathleen S ^a   Nelson, Kim L ^a   Ruzek, Melanie C ^a   Patel, Ketan ^a   Santucci, Zefferino ^a   Scarborough, Robert ^a   Wong, Rebecca S Y ^a   Bridger, Gary J ^a   MacFarland, Ron T ^a   Fricker, Simon P ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

AMD3465; Chemokine receptor; CXCR4; Leukocytosis; Pharmacokinetics

Indexed keywords

CALCIUM; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2B; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; GUANOSINE TRIPHOSPHATE; N [1,4,8,11 TETRAAZACYCLOTETRADECANYL 1,4 PHENYLENEBIS(METHYLENE)] 2 (AMINOMETHYL)PYRIDINE; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME BINDING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKOCYTOSIS; LIGAND BINDING; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STRUCTURE ACTIVITY RELATION;

ABSORPTION; ANIMALS; AREA UNDER CURVE; CALCIUM; CELL LINE; CHEMOKINE CXCL12; CHEMOTAXIS; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEINS; FLUORESCENT DYES; HALF-LIFE; HETEROCYCLIC COMPOUNDS; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; LEUKOCYTOSIS; MALE; MAXIMUM TOLERATED DOSE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; MOLECULAR STRUCTURE; PROTEIN BINDING; PYRIDINES; RECEPTORS, CXCR4; TRANSFECTION;

EID: 69349105658     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.010     Document Type: Article

References (43)

1. Baggiolini M., Dewald B., and Moser B. Human chemokines: an update. Annu Rev Immunol 15 (1997) 675-705
2. Zlotnik A., and Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 12 (2000) 121-127
3. Nagasawa T., Tachibana K., and Kishimoto T. A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection. Semin Immunol 10 (1998) 179-185
4. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996) 635-638
5. Baggiolini M. Chemokines and leukocyte traffic. Nature 392 (1998) 565-568
6. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., and Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184 (1996) 1101-1109
7. Aiuti A., Webb I.J., Bleul C., Springer T., and Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 185 (1997) 111-120
8. Peled A., Petit I., Kollet O., Magid M., Ponomaryov T., Byk T., et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283 (1999) 845-848
9. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382 (1996) 829-833
10. Feng Y., Broder C.C., Kennedy P.E., and Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272 (1996) 872-877
11. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382 (1996) 833-835
12. Bridger G.J., Skerlj R.T., Thornton D., Padmanabhan S., Martellucci S.A., Henson G.W., et al. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker. J Med Chem 38 (1995) 366-378
13. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., et al. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4 (1998) 72-77
14. Schols D., Este J.A., Henson G., and De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 35 (1997) 147-156
15. Hatse S., Princen K., Bridger G., De Clercq E., and Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527 (2002) 255-262
16. Fricker S.P., Anastassov V., Cox J., Darkes M.C., Grujic O., Idzan S.R., et al. Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochem Pharmacol 72 (2006) 588-596
17. Hendrix C.W., Collier A.C., Lederman M.M., Schols D., Pollard R.B., Brown S., et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 37 (2004) 1253-1262
18. Stone N.D., Dunaway S.B., Flexner C., Tierney C., Calandra G.B., Becker S., et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51 (2007) 2351-2358
19. Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Hubel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102 (2003) 2728-2730
20. Devine S.M., Flomenberg N., Vesole D.H., Liesveld J., Weisdorf D., Badel K., et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 1095-1102
21. Broxmeyer H.E., Orschell C.M., Clapp D.W., Hangoc G., Cooper S., Plett P.A., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 201 (2005) 1307-1318
22. Flomenberg N., Devine S.M., Dipersio J.F., Liesveld J.L., McCarty J.M., Rowley S.D., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106 (2005) 1867-1874
23. Calandra G., McCarty J., McGuirk J., Tricot G., Crocker S.A., Badel K., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 41 (2008) 331-338
24. Buckley C.D., Amft N., Bradfield P.F., Pilling D., Ross E., Arenzana-Seisdedos F., et al. Persistent induction of the chemokine receptor CXCR4 by TGF-β 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 165 (2000) 3423-3429
25. Nanki T., Hayashida K., El-Gabalawy H.S., Suson S., Shi K., Girschick H.J., et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol 165 (2000) 6590-6598
26. Matthys P., Hatse S., Vermiere K., Wuyts A., Bridger G., Henson G.W., et al. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol (2001) 1-7
27. Lukacs N.W., Berlin A., Schols D., Skerlj R.T., and Bridger G. AMD3100, a CXCR4 antagonist, attenuates allergic lung inflammation and airway hyperactivity. Am J Pathol 160 (2002) 1353-1360
28. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
29. Juarez J., and Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 19 (2004) 299-309
30. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14 (2004) 171-179
31. Bertolini F., Dell'Agnola C., Mancuso P., Rabascio C., Burlini A., Monestiroli S., et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Res 62 (2002) 3106-3112
32. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
33. Hatse S., Princen K., De Clercq E., Rosenkilde M.M., Schwartz T.W., Hernandez-Abad P.E., et al. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 70 (2005) 752-761
34. Labrecque J., Anastassov V., Lau G., Darkes M., Mosi R., and Fricker S.P. The development of an Europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol 3 (2005) 637-648
35. Larochelle A., Krouse A., Metzger M., Orlic D., Donahue R.E., Fricker S., et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood 107 (2006) 3772-3778
36. Burroughs L., Mielcarek M., Little M.T., Bridger G., Macfarland R., Fricker S., et al. Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood 106 (2005) 4002-4008
37. Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44 (2000) 1667-1673
38. Lack N.A., Green B., Dale D.C., Calandra G.B., Lee H., MacFarland R.T., et al. A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 77 (2005) 427-436
39. Gerlach L.O., Skerlj R.T., Bridger G.J., and Schwartz T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J Biol Chem 276 (2001) 14153-14160
40. Rosenkilde M.M., Gerlach L.O., Jakobsen J.S., Skerlj R.T., Bridger G.J., and Schwartz T.W. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J Biol Chem 279 (2004) 3033-3041
41. Rosenkilde M.M., Gerlach L.O., Hatse S., Skerlj R.T., Schols D., Bridger G.J., et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem 282 (2007) 27354-27365
42. Wong R.S., Bodart V., Metz M., Labrecque J., Bridger G., and Fricker S.P. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74 (2008) 1485-1495
43. Hu J.S., Freeman C.M., Stolberg V.R., Chiu B.C., Bridger G.J., Fricker S.P., et al. AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol 169 (2006) 424-432